Meenhard Herlyn

List of Publications by Citations

160 papers	18,908 citations	69 h-index	137 g-index
174 ext. papers	22,360 ext. citations	11.4 avg, IF	6.19 L-index

#	Paper	IF	Citations
160	Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. *Nature*, **2018**, 560, 382-386	50.4	1058
159	Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 3041-6	11.5	1056
158	A tumorigenic subpopulation with stem cell properties in melanomas. *Cancer Research*, **2005**, 65, 9328-37	10.1	1047
157	Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. *Cancer Cell*, **2010**, 18, 683-95	24.3	1007
156	A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. *Cell*, **2010**, 141, 583-94	56.2	874
155	BRAF and RAS mutations in human lung cancer and melanoma. *Cancer Research*, **2002**, 62, 6997-7000	10.1	735
154	Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. *Nature*, **2017**, 546, 431-435	50.4	544
153	A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. *Cell*, **2018** , 175, 984-997.e24	56.2	477
152	Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. *Cancer Cell*, **2013**, 23, 811-25	24.3	437
151	Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. *Molecular and Cellular Biology*, **2003**, 23, 14-25	4.8	397
150	Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. *Pigment Cell & Melanoma Research*, **2006**, 19, 290-302		378
149	Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. *Molecular Cancer Therapeutics*, **2006**, 5, 1136-44	6.1	372
148	Isolation of a novel population of multipotent adult stem cells from human hair follicles. *American Journal of Pathology*, **2006**, 168, 1879-88	5.8	299
147	Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. *Cancer Research*, **2003**, 63, 756-9	10.1	286
146	Melanoma. *Nature Reviews Disease Primers*, **2015**, 1, 15003	51.1	283
145	E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. *American Journal of Pathology*, **2000**, 156, 1515-25	5.8	275
144	Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. *Journal of Clinical Investigation*, **2005**, 115, 3166-76	15.9	258

143	Enhancing CD8 T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy. *Cancer Cell*, **2017**, 32, 377-391.e9	34.3	253
142	Adhesion, migration and communication in melanocytes and melanoma. *Pigment Cell & Melanoma Research*, **2005**, 18, 150-9		251
141	Rewired ERK-JNK signaling pathways in melanoma. *Cancer Cell*, **2007**, 11, 447-60	24.3	240
140	Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. *Nature Medicine*, **2018**, 24, 1545-1549	50.5	230
139	Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. *Cancer Research*, **2006**, 66, 4182-90	10.1	228
138	Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. *Cancer Discovery*, **2018**, 8, 196-215	24.4	228
137	Life isn't flat: taking cancer biology to the next dimension. *In Vitro Cellular and Developmental Biology - Animal*, **2006**, 42, 242-7	2.6	223
136	The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. *Frontiers in Bioscience - Landmark*, **2005**, 10, 2986-3001	2.8	208
135	An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. *Cancer Research*, **2007**, 67, 209-17	10.1	207
134	Epidermal growth factor receptor mediates increased cell proliferation, migration, and aggregation in esophageal keratinocytes in vitro and in vivo. *Journal of Biological Chemistry*, **2003**, 278, 1824-30	5.4	203
133	Melanoma-stroma interactions: structural and functional aspects. *Lancet Oncology, The*, **2002**, 3, 35-43	21.7	190
132	Suppression of nucleotide metabolism underlies the establishment and maintenance of oncogene-induced senescence. *Cell Reports*, **2013**, 3, 1252-65	10.6	177
131	Human melanoma progression in skin reconstructs : biological significance of bFGF. *American Journal of Pathology*, **2000**, 156, 193-200	5.8	177
130	Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. *American Journal of Pathology*, **1998**, 153, 1435-42	5.8	176
129	Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. *Journal of Clinical Investigation*, **2016**, 126, 1834-56	15.9	167
128	Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. *Cancer Discovery*, **2013**, 3, 1378-93	24.4	164
127	Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development. *Oncogene*, **2001**, 20, 8125-35	9.2	160
126	Expression of the receptor for epidermal growth factor correlates with increased dosage of chromosome 7 in malignant melanoma. *Somatic Cell and Molecular Genetics*, **1985**, 11, 297-302		150

125	Normal human melanocyte homeostasis as a paradigm for understanding melanoma. *Journal of Investigative Dermatology Symposium Proceedings*, **2005**, 10, 153-63	1.1	144
124	Melanoma and the tumor microenvironment. *Current Oncology Reports*, **2008**, 10, 439-46	6.3	143
123	Melanoma development and progression: a conspiracy between tumor and host. *Differentiation*, **2002**, 70, 522-36	3.5	143
122	Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. *Cell Reports*, **2013**, 4, 1090-9	10.6	141
121	Human dermal stem cells differentiate into functional epidermal melanocytes. *Journal of Cell Science*, **2010**, 123, 853-60	5.3	128
120	Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility. *Cancer Discovery*, **2019**, 9, 64-81	24.4	128
119	B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. *Nature Communications*, **2019**, 10, 4186	17.4	127
118	PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas. *Pigment Cell and Melanoma Research*, **2010**, 23, 820-7	4.5	122
117	Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion. *American Journal of Pathology*, **2005**, 166, 1541-54	5.8	122
116	Melanoma stem cells: the dark seed of melanoma. *Journal of Clinical Oncology*, **2008**, 26, 2890-4	2.2	120
115	The role of altered cell-cell communication in melanoma progression. *Journal of Molecular Histology* , **2004**, 35, 309-18	3.3	116
114	Fibroblast-dependent differentiation of human microvascular endothelial cells into capillary-like 3-dimensional networks. *FASEB Journal*, **2002**, 16, 1316-8	0.9	115
113	Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. *Oncogene*, **1999**, 18, 6469-76	9.2	107
112	Progression-related expression of beta3 integrin in melanomas and nevi. *Human Pathology*, **1999**, 30, 562-7	3.7	106
111	PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. *Nature*, **2017**, 550, 133-136	50.4	100
110	The essential role of fibroblasts in esophageal squamous cell carcinoma-induced angiogenesis. *Gastroenterology*, **2008**, 134, 1981-93	13.3	96
109	Defining the conditions for the generation of melanocytes from human embryonic stem cells. *Stem Cells*, **2006**, 24, 1668-77	5.8	95
108	Active Notch1 confers a transformed phenotype to primary human melanocytes. *Cancer Research*, **2009**, 69, 5312-20	10.1	93

107	Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing MAPK and PI3K/Akt pathways and requires MAML1. *FASEB Journal*, **2006**, 20, 1009-11	0.9	93
106	Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies. *Clinical Cancer Research*, **2016**, 22, 1592-602	12.9	91
105	A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT-competent cells that express the ZEB transcription factors. *Cancer Research*, **2011**, 71, 6836-47	10.1	91
104	Fibroblasts contribute to melanoma tumor growth and drug resistance. *Molecular Pharmaceutics*, **2011**, 8, 2039-49	5.6	90
103	A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. *Cell Reports*, **2017**, 21, 1953-1967	10.6	89
102	Therapeutic destruction of insulin receptor substrates for cancer treatment. *Cancer Research*, **2013**, 73, 4383-94	10.1	87
101	Dynamics of intercellular communication during melanoma development. *Trends in Molecular Medicine*, **2000**, 6, 163-9		86
100	In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. *Expert Opinion on Drug Discovery*, **2008**, 3, 1-10	6.2	83
99	CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. *Journal of Cell Biology*, **2006**, 175, 563-9	7.3	81
98	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. *Nature Communications*, **2017**, 8, 607	17.4	80
97	Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. *Cancer Research*, **2008**, 68, 5743-52	10.1	79
96	BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth. *Clinical Cancer Research*, **2015**, 21, 1652-64	12.9	78
95	The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. *Clinical Cancer Research*, **2013**, 19, 1784-94	12.9	74
94	Melanoma cell lines from different stages of progression and their biological and molecular analyses. *Melanoma Research*, **1997**, 7, S43	3.3	71
93	Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B. *Cancer Research*, **2004**, 64, 807-11	10.1	71
92	Functional erythropoietin autocrine loop in melanoma. *American Journal of Pathology*, **2005**, 166, 823-30	5.8	69
91	Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. *Oncogene*, **2001**, 20, 4676-84	9.2	67
90	Microenvironmental influences in melanoma progression. *Journal of Cellular Biochemistry*, **2007**, 101, 862-72	4.7	66

89	Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. *Pigment Cell and Melanoma Research*, **2015**, 28, 184-95	4.5	61
88	Developmental pathways activated in melanocytes and melanoma. *Archives of Biochemistry and Biophysics*, **2014**, 563, 13-21	4.1	57
87	The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. *Journal of Visualized Experiments*, **2011**,	1.6	54
86	Targeting CD20 in melanoma patients at high risk of disease recurrence. *Molecular Therapy*, **2012**, 20, 1056-62	11.7	54
85	Pre-clinical modeling of cutaneous melanoma. *Nature Communications*, **2020**, 11, 2858	17.4	53
84	Truncation of activated leukocyte cell adhesion molecule: a gateway to melanoma metastasis. *Journal of Investigative Dermatology*, **2004**, 122, 1293-301	4.3	51
83	Dermis-derived stem cells: a source of epidermal melanocytes and melanoma?. *Pigment Cell and Melanoma Research*, **2011**, 24, 422-9	4.5	49
82	The many faces of Notch signaling in skin-derived cells. *Pigment Cell & Melanoma Research*, **2007**, 20, 458-65		49
81	Selective evolutionary pressure from the tissue microenvironment drives tumor progression. *Seminars in Cancer Biology*, **2005**, 15, 451-9	12.7	48
80	The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. *PLoS ONE*, **2013**, 8, e59588	3.7	48
79	Direct reprogramming of melanocytes to neural crest stem-like cells by one defined factor. *Stem Cells*, **2011**, 29, 1752-62	5.8	47
78	Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. *Oncotarget*, **2017**, 8, 25395-25417	3.3	46
77	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. *Cell Reports*, **2017**, 21, 1936-1952	10.6	45
76	Growth and phenotypic characteristics of human nevus cells in culture. *Journal of Investigative Dermatology*, **1988**, 90, 134-41	4.3	45
75	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. *Nature Genetics*, **2021**, 53, 86-99	36.3	44
74	Polyunsaturated Fatty Acids from Astrocytes Activate PPAR[illegible]Signaling in Cancer Cells to Promote Brain Metastasis. *Cancer Discovery*, **2019**, 9, 1720-1735	24.4	43
73	Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. *EMBO Molecular Medicine*, **2018**, 10,	12	42
72	Heterogeneity in Melanoma. *Cancer Treatment and Research*, **2016**, 167, 1-15	3.5	41

71	In vitro growth patterns of normal human melanocytes and melanocytes from different stages of melanoma progression. *Journal of Immunotherapy*, **1992**, 12, 199-202	5	40
70	Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. *Cell Cycle*, **2011**, 10, 2008-16	4.7	37
69	VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells. *FASEB Journal*, **2003**, 17, 1931-3	0.9	34
68	Interactions of melanocytes and melanoma cells with the microenvironment. *Pigment Cell & Melanoma Research*, **1994**, 7, 81-8		34
67	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. *Nature Communications*, **2021**, 12, 346	17.4	34
66	Old disease, new culprit: tumor stem cells in cancer. *Journal of Cellular Physiology*, **2007**, 213, 603-9	7	33
65	Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase primary melanoma cells. *Cancer Research*, **2002**, 62, 226-32	10.1	33
64	GSK3 inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. *Journal of Investigative Dermatology*, **2012**, 132, 2818-27	4.3	30
63	Comparative secretome analysis of epithelial and mesenchymal subpopulations of head and neck squamous cell carcinoma identifies S100A4 as a potential therapeutic target. *Molecular and Cellular Proteomics*, **2013**, 12, 3778-92	7.6	30
62	Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. *Cancer Discovery*, **2020**, 10, 1282-1295	24.4	29
61	Matricellular proteins produced by melanocytes and melanomas: in search for functions. *Cancer Microenvironment*, **2008**, 1, 93-102	6.1	29
60	Reversal of melanocytic malignancy by keratinocytes is an E-cadherin-mediated process overriding beta-catenin signaling. *Experimental Cell Research*, **2004**, 297, 142-51	4.2	29
59	JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers. *Cancer Research*, **2016**, 76, 5538-49	10.1	28
58	Crosstalk in skin: melanocytes, keratinocytes, stem cells, and melanoma. *Journal of Cell Communication and Signaling*, **2016**, 10, 191-196	5.2	27
57	Oncogenic RAS Regulates Long Noncoding RNA in Human Cancer. *Cancer Research*, **2017**, 77, 3745-3757	10.1	25
56	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. *Cancer Research*, **2020**, 80, 4314-4323	10.1	25
55	Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations. *Experimental Dermatology*, **2015**, 24, 155-7	4	24
54	Paradoxical Role for Wild-Type p53 in Driving Therapy Resistance in Melanoma. *Molecular Cell*, **2020** , 77, 633-644.e5	17.6	24

53	Melanoma models for the next generation of therapies. *Cancer Cell*, **2021**, 39, 610-631	24.3	23
52	EGFR inhibition promotes an aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous cell carcinomas. *Molecular Cancer Therapeutics*, **2013**, 12, 2176-86	6.1	22
51	Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. *Clinical Cancer Research*, **2018**, 24, 4771-4784	12.9	21
50	MSX1-Induced Neural Crest-Like Reprogramming Promotes Melanoma Progression. *Journal of Investigative Dermatology*, **2018**, 138, 141-149	4.3	20
49	ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma. *Cancer Research*, **2017**, 77, 5873-5885	10.1	20
48	The role of Orai-STIM calcium channels in melanocytes and melanoma. *Journal of Physiology*, **2016**, 594, 2825-35	3.9	19
47	BRAF Targeting Sensitizes Resistant Melanoma to Cytotoxic T Cells. *Clinical Cancer Research*, **2019**, 25, 2783-2794	12.9	18
46	Targeting the stromal fibroblasts: a novel approach to melanoma therapy. *Expert Review of Anticancer Therapy*, **2005**, 5, 1069-78	3.5	17
45	IspH inhibitors kill Gram-negative bacteria and mobilize immune clearance. *Nature*, **2021**, 589, 597-602	50.4	17
44	Nivolumab in combination with ipilimumab for the treatment of melanoma. *Expert Review of Anticancer Therapy*, **2015**, 15, 1135-41	3.5	16
43	UV-Induced Wnt7a in the Human Skin Microenvironment Specifies the Fate of Neural Crest-Like Cells via Suppression of Notch. *Journal of Investigative Dermatology*, **2015**, 135, 1521-1532	4.3	15
42	Isolation and cultivation of dermal stem cells that differentiate into functional epidermal melanocytes. *Methods in Molecular Biology*, **2012**, 806, 15-29	1.4	14
41	Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy. *International Journal of Cancer*, **2009**, 124, 1245-50	7.5	14
40	Molecular targets in melanoma: strategies and challenges for diagnosis and therapy. *International Journal of Cancer*, **2006**, 118, 523-6	7.5	14
39	Large-Scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines. *Cancer Cell*, **2020**, 38, 829-843.e4	24.3	13
38	Isolation, characterization, and differentiation of human multipotent dermal stem cells. *Methods in Molecular Biology*, **2013**, 989, 235-46	1.4	12
37	Evolution of delayed resistance to immunotherapy in a melanoma responder. *Nature Medicine*, **2021**, 27, 985-992	50.5	11
36	Enhancing the evaluation of PI3K inhibitors through 3D melanoma models. *Pigment Cell and Melanoma Research*, **2016**, 29, 317-28	4.5	11

35	The State of Melanoma: Emergent Challenges and Opportunities. *Clinical Cancer Research*, **2021**, 27, 2678-2697	12.9	11
34	Recent Advances in Melanoma and Melanocyte Biology. *Journal of Investigative Dermatology*, **2017**, 137, 557-560	4.3	10
33	Beyond ABC: another mechanism of drug resistance in melanoma side population. *Journal of Investigative Dermatology*, **2012**, 132, 2317-2319	4.3	10
32	Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. *Clinical Cancer Research*, **2020**, 26, 6039-6050	12.9	9
31	A Melanoma Patient-Derived Xenograft Model. *Journal of Visualized Experiments*, **2019**,	1.6	8
30	Driving in the melanoma landscape. *Experimental Dermatology*, **2009**, 18, 506-8	4	8
29	Frontiers in pigment cell and melanoma research. *Pigment Cell and Melanoma Research*, **2018**, 31, 728-735	4.5	8
28	Targeting the cyclin-dependent kinase 5 in metastatic melanoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 8001-8012	11.5	7
27	Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling. *Cancer Discovery*, **2021**, 11, 1716-1735	24.4	6
26	Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. *Oncogene*, **2021**, 40, 5590-5599	9.2	6
25	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment. *Nature Communications*, **2021**, 12, 5086	17.4	6
24	Metastatic melanoma cells. Introduction. *Cancer and Metastasis Reviews*, **2005**, 24, 193-4	9.6	5
23	Pre-determined diversity in resistant fates emerges from homogenous cells after anti-cancer drug treatment		5
22	ARID2 Deficiency Correlates with the Response to Immune Checkpoint Blockade in Melanoma. *Journal of Investigative Dermatology*, **2021**, 141, 1564-1572.e4	4.3	5
21	Persister state-directed transitioning and vulnerability in melanoma. *Nature Communications*, **2022**, 13,	17.4	5
20	There is a world beyond protein mutations: the role of non-coding RNAs in melanomagenesis. *Experimental Dermatology*, **2013**, 22, 303-6	4	4
19	Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma. *Oncogene*, **2021**, 40, 1659-1673	9.2	4
18	SPANX Control of Lamin A/C Modulates Nuclear Architecture and Promotes Melanoma Growth. *Molecular Cancer Research*, **2020**, 18, 1560-1573	6.6	3

17	Combination therapy of immunocytokines with ipilimumab: a cure for melanoma?. *Journal of Investigative Dermatology*, **2013**, 133, 595-596	4.3	3
16	Roadmap for new opportunities in melanoma research. *Seminars in Oncology*, **2007**, 34, 566-76	5.5	3
15	Embryonic stem cells as a model for studying melanocyte development. *Methods in Molecular Biology*, **2010**, 584, 301-16	1.4	3
14	Nongenetic Mechanisms of Drug Resistance in Melanoma. *Annual Review of Cancer Biology*, **2020**, 4, 315-330	13.9	3
13	Inhibiting insulin and mTOR signaling by afatinib and crizotinib combination fosters broad cytotoxic effects in cutaneous malignant melanoma. *Cell Death and Disease*, **2020**, 11, 882	9.8	3
12	TRIM15 and CYLD regulate ERK activation via lysine-63-linked polyubiquitination. *Nature Cell Biology*, **2021**, 23, 978-991	23.4	3
11	Costimulation of [illegible]CR and TLR7/8 promotes V[illegible] T-cell antitumor activity by modulating mTOR pathway and APC function. **2021**, 9,		3
10	Establishing Human Skin Grafts in Mice as Model for Melanoma Progression. *Methods in Molecular Biology*, **2015**, 1	1.4	1
9	Farming cells to rebuild skin and melanoma. *Cancer Biology and Therapy*, **2007**, 6, 467-71	4.6	1
8	Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. *Nature Communications*, **2021**, 12, 6023	17.4	1
7	Large-scale Characterization of Drug Responses of Clinically Relevant Proteins in Cancer Cell Lines		1
6	Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. *Cancer Research*, **2021**, 81, 5230-5241	10.1	1
5	PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.. *NAR Cancer*, **2022**, 4, zcac014	5.2	1
4	Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.. *Nature Communications*, **2022**, 13, 1381	17.4	0
3	Boris Bastian. *Pigment Cell and Melanoma Research*, **2010**, 23, 834	4.5	
2	Role of stem cells in melanoma progression: hopes for a better treatment. *Expert Review of Dermatology*, **2007**, 2, 191-201		
1	Targeting BRAF/MEK in melanoma: new hope or another false dawn?. *Expert Review of Dermatology* , **2007**, 2, 179-190		